Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification
| Autor: | Jaffer A. Ajani, Xuemei Wang, Allison Trail, Meina Zhao, Jeannelyn S. Estrella, Jane E. Rogers, Ahmed K. Abdelhakeem, Mariela Blum-Murphy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Esophageal Neoplasms Receptor ErbB-2 Gastroesophageal cancer Stomach Neoplasms Internal medicine Gene duplication ERBB2 Gene Amplification Biomarkers Tumor Medicine Humans skin and connective tissue diseases neoplasms In Situ Hybridization Fluorescence Aged Aged 80 and over medicine.diagnostic_test business.industry Gene Amplification General Medicine Oncogenes Middle Aged Immunohistochemistry Confidence interval Progression-Free Survival Gene Expression Regulation Neoplastic Cohort Fish Female business Fluorescence in situ hybridization |
| Zdroj: | Oncology. 98(12) |
| ISSN: | 1423-0232 |
| Popis: | Background: Prior studies have shown that patients whose tumor overexpresses Her2 at 3+ level by immunohistochemistry (IHC) fare better than those whose tumor overexpresses Her2 at 2+ level (with ERBB2 amplified). Therefore, it would be important to compare the outcome of patients whose tumor expresses Her2 at 2+ level but further classify by gene amplification studies as positive or negative. Methods: We retrospectively identified patients with advanced gastroesophageal adenocarcinoma with low Her2 protein expression (2+ by IHC) whose tumors were evaluated for gene amplification of ERBB2 by fluorescence in situ hybridization (FISH). All patients received first-line therapy, and trastuzumab was added according to Her2 status. We compared overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) of the entire cohort and compared Her2-positive tumor patients’ outcomes with Her2-negative tumor patients’ outcomes. All patients had treatment response assessments and follow-ups at our institution. Results: We identified 87 patients whose tumors expressed Her2 at 2+ level. 51 (58.6%) were Her2-negative and 36 (41.4%) were Her2-positive by FISH. For the entire cohort, the median OS was 26 months (95% confidence interval 16.6–37.6), and the median PFS was 12.2 months (95% confidence interval 9.7–19.3). Median OS, median PFS, and ORR did not differ between Her2-positive and Her2-negative patients (p = 0.70, p = 0.60, p = 0.91, respectively). Conclusions: Our data suggest that patients with Her2 positivity or negativity when tumors have lower Her2 protein expression (2 + by IHC) have similar clinical outcomes. Further research is warranted in this cohort. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|